ArticleThe Journal of biological chemistry2017

Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.

Kush Dalal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.